Document is current
Any future updates will be listed below
-
Authors
Chung, Kuei-Pin https://orcid.org/0000-0003-1916-8068
Cheng, Chih-Ning
Chen, Yi-Jung
Hsu, Chia-Lang https://orcid.org/0000-0002-7447-8045
Huang, Yen-Lin
Hsieh, Min-Shu
Kuo, Han-Chun
Lin, Ya-Ting
Juan, Yi-Hsiu
Nakahira, Kiichi https://orcid.org/0000-0003-4871-0178
Chen, Yen-Fu
Liu, Wei-Lun
Ruan, Sheng-Yuan
Chien, Jung-Yien
Plataki, Maria
Cloonan, Suzanne M. https://orcid.org/0000-0001-5301-9926
Carmeliet, Peter https://orcid.org/0000-0001-7961-1821
Choi, Augustine M. K.
Kuo, Ching-Hua https://orcid.org/0000-0001-5722-0360
Yu, Chong-Jen https://orcid.org/0000-0001-5664-9392
- License Information
-
More Information
Article History
Received: 1 October 2023
Accepted: 13 August 2024
First Online: 22 August 2024
Competing interests
: A.M.K.C. is a cofounder and equity stockholder for Proterris, which develops therapeutic uses for CO. A.M.K.C. has a use patent on CO. Additionally, A.M.K.C. has patents in chronic obstructive pulmonary disease (US Patent 10905682). M.P. participates an advisory board meeting for InflaRx. All the other authors declare no competing interests.
